In Other News

• ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026

• ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026

• Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

• Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

• Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests

• Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

• New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays

• Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

• Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers

• Artera to Highlight AI-Based Cancer Risk Stratification at ASCO 2026

• Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation

• AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

• FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets

• Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma

• Gene Fusion Patterns May Flag High Risk Solitary Fibrous Tumors

• Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders

• Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026

• Fujifilm Integrates Structured Reporting into Digital Pathology Workflow

• Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers

• Fujifilm Integrates Structured Reporting into Digital Pathology Workflow

• New RNA Origami Method Supports Faster Targeted Testing for Repeat Expansion Disorders

• Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals

• New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients